Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566

Annals of Oncology

Volumn 12, Issue 3, 2001, Pages 389-395

  Erlichman, C ^a   Adjei, A A ^a   Alberts, S R ^a   Sloan, J A ^a   Goldberg, R M ^a   Pitot, H C ^a   Rubin, J ^a   Atherton, P J ^a   Klee, G G ^a   Humphrey, R ^b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Antimetastatic; Gelatinase A; Gelatinase B; Inhibitor; Matrixmetalloproteinase

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DEOXYPYRIDINOLINE; GELATINASE A; GELATINASE B; MARKER; MATRIX METALLOPROTEINASE INHIBITOR; PYRIDINOLINE; STROMELYSIN; TANOMASTAT; VASCULOTROPIN;

ADULT; ANEMIA; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LUNG CANCER; MALE; METASTASIS; MUSCULOSKELETAL DISEASE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; URINE LEVEL;

EID: 0035071939     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011183905848     Document Type: Article

References (25)

1. Matrix metalloproteinases in immunity
2. Changing views of the role of matrix metalloproteinases in metastasis
3. Complex roles of matrix metalloproteinases in tumor progression
4. Regulation of matrix metalloproteinase activity
5. Proteinases and inhibitors
6. Matrix metalloproteinases and their inhibitors in tumor progression
7. Matrix metalloproteinase inhibition: A review of anti-tumour activity
8. Matrix metalloproteinases inhibiting drugs
9. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models
10. Anti-invasive and anti-metastatic activity of the novel MMP inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT 116
11. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice
12. AY 12-9566, a novel biphenyl matrix metalloproteinase inhibitor demonstrates anti-invasive and anti-angiogenic properties
13. Pre-clinical drug safety profile for the antimetastatic matrix metalloproteinase inhibitory agent BAY 12-9566
14. Quantitative HPLC analysis of f Λ-[Δ-4-(chlorophenyl) phenyl]-4-oxo-2S (phenylthiomethyl) butanoic acid (BAY 12-9566), a metalloproteinase inhibitor and its metabolites in human plasma
15. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
16. Biochemical markers of bone turnover in patients with metastatic bone disease
17. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
18. Phase I study of the metalloproteinase inhibitor Bayer 12-9566
19. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566
20. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
21. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
22. Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer
23. Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer
24. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - A predictor of tumour stage